Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

ILEANA LIVIA PINA

Allopathic & Osteopathic Physicians Internal Medicine Advanced Heart Failure and Transplant Cardiology

NPI
1144240771
CMS profile
324327
Location
PHILADELPHIA, PA

General Payments · PY2018–2024

$275,827.14

  • Reported across 262 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$32,482.07

31 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $28,915.36 45
PY2019 $57,924.85 80
PY2020 $22,641.54 21
PY2021 $22,924.65 15
PY2022 $52,163.67 33
PY2023 $58,775.00 37
PY2024 $32,482.07 31

Payment records · PY2024 (31)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AstraZeneca Pharmaceuticals LP $83.19 01/25/2024 Food and Beverage Undisputed 01/23/2026 1104570716 CMS
AstraZeneca Pharmaceuticals LP $6,075.00 03/15/2024 Grant Undisputed 01/23/2026 1104321824 CMS
AstraZeneca Pharmaceuticals LP $15.39 03/15/2024 Food and Beverage Undisputed 01/23/2026 1105805702 CMS
AstraZeneca Pharmaceuticals LP $108.59 04/07/2024 Food and Beverage Undisputed 01/23/2026 1104448489 CMS
AstraZeneca Pharmaceuticals LP $25.19 06/28/2024 Food and Beverage Undisputed 01/23/2026 1105588440 CMS
AstraZeneca Pharmaceuticals LP $27.16 07/18/2024 Food and Beverage Undisputed 01/23/2026 1104247771 CMS
AstraZeneca Pharmaceuticals LP $63.14 07/18/2024 Food and Beverage Undisputed 01/23/2026 1105261730 CMS
AstraZeneca Pharmaceuticals LP $26.96 11/16/2024 Food and Beverage Undisputed 01/23/2026 1105678943 CMS
AstraZeneca UK Limited $77.32 08/30/2024 Food and Beverage Undisputed 01/23/2026 1093926803 CMS
Boehringer Ingelheim International GmbH $5,396.30 09/30/2024 Travel and Lodging Undisputed 01/23/2026 1117888757 CMS
Boehringer Ingelheim International GmbH $6,637.50 09/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1117888759 CMS
Boehringer Ingelheim International GmbH $1,600.00 10/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1117888753 CMS
Boehringer Ingelheim International GmbH $2,212.50 11/14/2024 Consulting Fee Undisputed 01/23/2026 1117888755 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $123.40 05/02/2024 Food and Beverage Undisputed 01/23/2026 1117888751 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $114.17 10/02/2024 Food and Beverage Undisputed 01/23/2026 1117888749 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.45 10/03/2024 Food and Beverage Undisputed 01/23/2026 1117888743 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $77.81 11/15/2024 Food and Beverage Undisputed 01/23/2026 1117888747 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $68.31 12/12/2024 Food and Beverage Undisputed 01/23/2026 1117888745 CMS
E.R. Squibb & Sons, L.L.C. $48.60 09/17/2024 Food and Beverage Undisputed 01/23/2026 1101343041 CMS
E.R. Squibb & Sons, L.L.C. $127.84 09/17/2024 Food and Beverage Undisputed 01/23/2026 1101343043 CMS
E.R. Squibb & Sons, L.L.C. $32.40 09/17/2024 Food and Beverage Undisputed 01/23/2026 1101343045 CMS
E.R. Squibb & Sons, L.L.C. $16.20 09/17/2024 Food and Beverage Undisputed 01/23/2026 1101343047 CMS
E.R. Squibb & Sons, L.L.C. $21.60 09/17/2024 Food and Beverage Undisputed 01/23/2026 1101343049 CMS
E.R. Squibb & Sons, L.L.C. $60.48 09/17/2024 Food and Beverage Undisputed 01/23/2026 1101343051 CMS
E.R. Squibb & Sons, L.L.C. $4,775.00 10/17/2024 Consulting Fee Undisputed 01/23/2026 1101343019 CMS
Eli Lilly and Company $2,450.00 11/22/2024 Consulting Fee Undisputed 01/23/2026 1134985400 CMS
Eli Lilly and Company $2,100.00 11/22/2024 Consulting Fee Undisputed 01/23/2026 1135026612 CMS
Merck Sharp & Dohme LLC $50.42 11/16/2024 Food and Beverage Undisputed 01/23/2026 1141565941 CMS
Novartis Pharmaceuticals Corporation $14.85 05/16/2024 Food and Beverage Undisputed 01/23/2026 1087257217 CMS
Novartis Pharmaceuticals Corporation $14.35 08/28/2024 Food and Beverage Undisputed 01/23/2026 1087257221 CMS
Novartis Pharmaceuticals Corporation $15.95 10/02/2024 Food and Beverage Undisputed 01/23/2026 1087257225 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.